<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PSA Rising Prostate Cancer Blog &#187; Metastatic</title>
	<atom:link href="http://www.psa-rising.com/blog/category/pca/metastatic/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.psa-rising.com/blog</link>
	<description></description>
	<lastBuildDate>Tue, 16 Aug 2011 09:39:00 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>New Pathway to Potential Therapies for Advanced Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/</link>
		<comments>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/#comments</comments>
		<pubDate>Wed, 27 Jul 2011 19:47:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Castration Resistant]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Avodart]]></category>
		<category><![CDATA[CRPC]]></category>
		<category><![CDATA[SRD5A]]></category>
		<category><![CDATA[Zytiga]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2402</guid>
		<description><![CDATA[PSA Rising /DALLAS/ – July 25, 2011 – UT Southwestern Medical Center researchers have narrowed the potential drug targets for advanced prostate cancer by demonstrating that late-stage tumors are driven by a different hormonal pathway than previously was thought. &#8220;We have recently discovered that castration resistant prostate cancer (CRPC) is unexpectedly driven by dihydrotestosterone synthesis [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2011/07/new-pathway-to-potential-therapies-for-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Provenge available for men with advanced prostate cancer at Roswell Park</title>
		<link>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/</link>
		<comments>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/#comments</comments>
		<pubDate>Wed, 16 Feb 2011 00:39:59 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Hormone refractory]]></category>
		<category><![CDATA[Immunotherapy]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Provenge]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Add new tag]]></category>
		<category><![CDATA[Advanced PCa]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2368</guid>
		<description><![CDATA[February 7 2011, BUFFALO, NY — The nation’s first FDA-approved cancer treatment vaccine, Provenge (sipuleucel-T), is being offered for the first time in Western New York at Roswell Park Cancer Institute (RPCI). The vaccine is designed for men with advanced prostate cancer who have limited treatment options and who meet eligibility requirements. “It’s the first [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2011/02/provenge-available-for-men-with-advanced-pca-at-roswell-park/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Phase 3 Trial Underway for MDV 3100 for Advanced Prostate Cancer</title>
		<link>http://www.psa-rising.com/blog/2010/04/mdv3100-trial-phase3/</link>
		<comments>http://www.psa-rising.com/blog/2010/04/mdv3100-trial-phase3/#comments</comments>
		<pubDate>Thu, 15 Apr 2010 19:58:54 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[MDV 3100]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[trial results]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=2280</guid>
		<description><![CDATA[In light of favorable results from the Phase 1-2 trial of MDV 3100 for advanced prostate cancer, a Phase 3 trial is enrolling at sites in the US, Canada, South America, UK, Europe, Australia, and South Africa. Results from the earlier trial are published online by the UK medical journal The Lancet. Phase 3 Trial [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2010/04/mdv3100-trial-phase3/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Degarelix Effect Compared to Lupron</title>
		<link>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/</link>
		<comments>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/#comments</comments>
		<pubDate>Sat, 27 Dec 2008 10:26:26 +0000</pubDate>
		<dc:creator>jacquie strax</dc:creator>
				<category><![CDATA[degarelix]]></category>
		<category><![CDATA[Hormonal-ADT]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[PCa Treatments]]></category>
		<category><![CDATA[Prostate Cancer]]></category>

		<guid isPermaLink="false">http://www.psa-rising.com/blog/?p=825</guid>
		<description><![CDATA[Below are a graph and a table of the effect of Ferring&#8217;s degarelix on testosterone compared with the effect of Lupron. On December 24th Ferring announced that FDA has approved degarelix for the treatment of hormonally sensitive advanced prostate cancer. Degarelix (generic name) is a GnRH receptor antagonist. The company says: &#8220;Degarelix achieves medical castration [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2008/12/degarelix-effect-compared-to-lupron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Ambrilia&#8217;s peptide for metastatic prostate cancer, Phase I/II results</title>
		<link>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/</link>
		<comments>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/#comments</comments>
		<pubDate>Tue, 24 Apr 2007 10:19:53 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Clinical trials]]></category>
		<category><![CDATA[Metastatic]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Ambrilia]]></category>
		<category><![CDATA[PCK3145]]></category>

		<guid isPermaLink="false">http://psa-rising.com/blog/index.php/2007/04/24/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/</guid>
		<description><![CDATA[Ambrilia, a Montreal company, said today that results of a Phase I/II trial of PCK3145 in patients with metastatic prostate cancer show that the drug, a small molecule peptide, slows tumor doubling time.. Previously, detailed Phase I results were presented at ASCO and are online: Slovin, S., et al. Phase I trial results of PCK3145 [...]]]></description>
		<wfw:commentRss>http://www.psa-rising.com/blog/2007/04/amrilias-peptide-drug-for-metastic-prostate-cancer-phase-iii-results/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

